Dr BOUSTANI Jihane

Fiche personne

Coordonnées

Hôpital Jean Minjoz
3 bd Fleming
25030 BESANCON Cedex

Territoire

Franche-Comté

Statut

Hospitalier

Affiliation

Centre hospitalier régional universitaire de Besançon (CHRU Besançon)

Projets

Etude des réponses immunitaires T antitumorales chez des patients pris en charge pour une tumeur infiltrante ou non de la vessie (IMMUNO-BLAD)

2023 - Porteur du projet : Dr BOUSTANI Jihane

Publications

Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective Study.

Mezepo G, Khene ZE, Boustani J, Kleinclauss F, Quivrin M, Neftah Y, Mercier J, Bajeot AS, Mardelli C, Pradere B, Seisen T, Hammoud Y, Bouvier E, Jacquey H, Choffel L, Palkowski T, Khalifa J, Benyoucef A, Pasquier D, Brassart C, Marcq G, Khalladi N, Coutte A, Sargos P, Huck C, Rouprêt M, Roumiguie M,

Eur Urol Oncol. 2026 01 22;:

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Kim S, Boustani J, Iseas S, Vernerey D, Evesque L, Quero L, Ghiringhelli F, Coutzac C, Bouché O, Chibaudel B, Vernet C, Vienot A, Tougeron D, Nguyen T, Rebucci-Peixoto M, Meurisse A, Chennoufi S, Maritaz C, Borg C,

Lancet Oncol. 2025 11 4;:

Role of radiotherapy in the management of testicular cancer: Recommendations from the French society for radiation oncology.

Raynaud C, Supiot S, Le Guévelou J, Blanchard P, Boustani J, Rogé M, Roubaud G, Marchesi V, Latorzeff I, Sargos P

Cancer Radiother. 2025 09 10;29(7-8):104712

Urinary organs-at-risk for radiotherapy following radical prostatectomy: contouring guidelines on behalf of the Francophone Group of Urological Radiation Therapy (GFRU).

Guevelou JL, Zilli T, Peyrottes A, Beuzit L, Ferretti L, Terlizzi M, Supiot S, Achard V, Palumbo S, Loos G, Boustani J, Salembier C, Sargos P

Pract Radiat Oncol. 2025 09 4;:

Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K,

Lancet. 2024 11 23;404(10467):2065-2076

Enzyme-linked ImmunoSpot (ELISpot) assay to quantify peptide-specific IFN-γ production by splenocytes in a mouse tumor model after radiation therapy.

Lecoester B, Xie Y, Marguier A, Boulerot L, Malfroy M, Adotévi O, Boustani J

Methods Cell Biol. 2024 09 5;189:41-54

Definitive radio(chemo)therapy versus upfront surgery in the treatment of HPV-related localized or locally advanced oropharyngeal squamous cell carcinoma.

Baude J, Guigou C, Thibouw D, Vulquin N, Folia M, Constantin G, Boustani J, Duvillard C, Ladoire S, Truc G, Bertaut A, Chevalier C

PLoS One. 2024 07 25;19(7):e0307658

A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ study.

Zaidi F, Calame P, Chevalier C, Henriques J, Vernerey D, Vuitton L, Heyd B, Borg C, Boustani J

Radiat Oncol. 2024 07 15;19(1):90

Management of Graves' ophthalmopathy by radiotherapy: A literature review.

Beige A, Boustani J, Bouillet B, Truc G

Cancer Radiother. 2024 06 20;:

Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.

Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C

Int J Radiat Biol. 2024 03 20;:1-10

Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021-2023.

Boustani J, Huguet F, Vendrely V

Cancer Radiother. 2023 12;27(8):768-777

Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU).

Ah-Thiane L, Sargos P, Chapet O, Jolicoeur M, Terlizzi M, Salembier C, Boustani J, Prevost C, Gaudioz S, Derashodian T, Palumbo S, De Hertogh O, Créhange G, Zilli T, Supiot S

Cancer Treat Rev. 2023 09 16;120:102626

Contribution of chemotherapy in immunoradiotherapy combinations.

Xie Y, Lecoester B, Boustani J

Cancer Radiother. 2023 07 24;:

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.

Meunier S, Frontczak A, Balssa L, Blanc J, Benhmida S, Pernot M, Quivrin M, Martin E, Hammoud Y, Créhange G, Boustani J

Cancers (Basel). 2023 03 21;15(6):

Chemotherapy to potentiate the radiation-induced immune response.

Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O

Int Rev Cell Mol Biol. 2023 02 11;376:143-173

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma.

Hervé L, Kim S, Boustani J, Klajer E, Pernot M, Nguyen T, Lakkis Z, Borg C, Vienot A

Front Oncol. 2022 11 17;12:974108

[Dose-escalated radiotherapy in esophageal cancer: A review of the literature].

Boustani J, Créhange G

Cancer Radiother. 2022 10;26(6-7):884-889

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Kim S, Boustani J, Vernerey D, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C

Front Oncol. 2022 08 24;12:918499

Salvage Involved-Field and Extended-Field Radiation Therapy in Positron Emission Tomography-Positive Nodal Recurrent Prostate Cancer: Outcomes and Patterns of Failure.

Pêtre A, Quivrin M, Briot N, Boustani J, Martin E, Bessieres I, Cochet A, Créhange G

Adv Radiat Oncol. 2022 07 28;8(1):101040

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J

Front Oncol. 2022 07 22;12:918271

Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26).

Crehange G, M'vondo C, Bertaut A, Pereira R, Rio E, Peiffert D, Gnep K, Benezery K, Ronchin P, Noel G, Mineur L, Drouillard A, Blanc J, Rouffiac M, Boustani J

Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S5

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies.

Boustani J, Lecoester B, Baude J, Latour C, Adotevi O, Mirjolet C, Truc G

Cancers (Basel). 2021 Sep 29;13(19):

Present and Future Research on Anal Squamous Cell Carcinoma.

Spehner L, Boustani J, Cabel L, Doyen J, Vienot A, Borg C, Kim S

Cancers (Basel). 2021 Aug 2;13(15):

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.

Bolla M, Neven A, Maingon P, Carrie C, Boladeras A, Andreopoulos D, Engelen A, Sundar S, van der Steen-Banasik EM, Armstrong J, Peignaux-Casasnovas K, Boustani J, Herrera FG, Pieters BR, Slot A, Bahl A, Scrase CD, Azria D, Jansa J, O'Sullivan JM, Van Den Bergh ACM, Collette L,

J Clin Oncol. 2021 Jul 26;:JCO2100855

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.

Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O

J Immunother Cancer. 2021 Jul;9(7):

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O

BMC Immunol. 2021 Jun 18;22(1):38

Long-term outcomes and safety after reirradiation in locally recurrent nasopharyngeal carcinoma in a non-endemic area.

Boustani J, Ruffier A, Moya-Plana A, Tao Y, Nguyen F, Even C, Berthold C, Casiraghi O, Temam S, Blanchard P

Strahlenther Onkol. 2021 03;197(3):188-197

Glassy cell carcinoma of the uterine cervix: 20-year experience from a comprehensive cancer center.

Boustani J, Achkar S, Bertaut A, Genestie C, Gouy S, Pautier P, Morice P, Haie-Meder C, Chargari C

Cancer Radiother. 2021 Jan 3;:

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

Quality Assurance of Dose Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal Cancer.

Boustani J, Del Campo ER, Blanc J, Peiffert D, Benezery K, Pereira R, Rio E, Le Prisé E, Créhange G, Huguet F

Int. J. Radiat. Oncol. Biol. Phys.. 2019 Jul 9;:

The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response.

Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C

Cancers (Basel). 2019 Jun 20;11(6):

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G,

Acta Oncol. 2017 Aug;:1-7